Here We KDIGO Again: Lupus Nephritis 2024
New KDIGO guidelines since 2021, Lupus Nephritis is seeing lots of new therapeutics in the pipeline.
New KDIGO guidelines since 2021, Lupus Nephritis is seeing lots of new therapeutics in the pipeline.
Fascinating observational study on hyponatraemia correction rates this week, catch-up here.
TenTweetNephJC on X. Natriuresis guidance for intensification of diuretics is one strategy to PUSH decongestion in patient’s with acute heart failure.
TenTweetNephJC on AIN = TenXNephJC on AIN = XXNephJC on AIN…? Twitter not being called twitter is confusing.
Patients are given a lot of fluid post-transplant, but which to choose? Catch up on the latest evidence here.
Huge trial on our core work, catch-up here
WIth no RCTs to go on, we review a meta-analysis on sodium thiosulphate for calciphylaxis
RCT of PO sodium bicarbonate in patients with renal transplant to see if impacts stability of renal function - catch up here!
Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
Huge news in APOL1 nephropathy - ten tweets to fill you in here:
Thiazides to prevent rolling stones - the Ten Tweet summary of NOSTONE is here.
Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
It’s a controversial topic: click below to catch-up
Now that twitter has recovered from its downtime, a catch-up tweetorial on apixaban for AF in patients on dialysis for you.
What’s your loop and thiazide of choice? Do you know which diuretics are better, faster, stronger? This week’s TenTweets is a two-fer (Chlorthalidone vs HCTZ and Furosemide vs Torsemide). Tweetorial catch-up here.
The bad news is it was on bardoxolone. Tweetorial catch-up here.
Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
The last NephJC of the year brought us a cool discussion on if cooling dialysate could help mitigate the effects of intradialytic hypotension. Get caught up with the chat in the latest edition of #TenTweetNephJC.
This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!
If you missed the biggest NephJC of the year, at least read the highlights here.